Merus NV (NASDAQ: MRUS) is a clinical-stage oncology company developing bispecific antibody therapeutics for solid tumours and blood cancers. Its Biclonics® platform creates antibodies that bind to two targets simultaneously, aiming to improve tumour specificity and immune activation. With multiple candidates in mid- to late-stage trials and partnerships with leading biopharma firms, Merus is a high-potential player in next-generation cancer immunotherapy.
差價合約 (CFD) 是一種複雜的金融工具，利用槓桿交易雖然可能放大收益，但同樣也會加劇虧損風險，導致資金快速流失。數據顯示，79.58% 的散戶投資者在使用該提供商服務進行差價合約交易時出現帳戶虧損。在進行交易之前，請確保您充分了解差價合約的運作機制，並仔細評估自己是否有能力承擔資金虧損的高風險。
評級和評論
評級和評論
